EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)

Chuanhua Zhao, Jun Zhao, Yigui Chen, Bo Liu, Yangfeng Du, Chenglin Li, Jingdong Zhang, Mudan Yang, Ying Liu, Yuxian Bai, Suyi Li, Ruixing Zhang und 7 weitere

Cancer Communications · 2025-12 · 45 (12) · 1755-1759

DOI: 10.1002/cac2.70080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 22.11.2025. Verfasst von Chuanhua Zhao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, Chinese PLA General Hospital, Beijing, P. R. China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai JMT-Bio Technology Co., Ltd.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Senior Department of Oncology, Chinese PLA General Hospital, Beijing, P. R. China.
  • Department of Oncology, Changzhi People's Hospital, Changzhi, Shanxi, P. R. China.
  • Department of Medicine, Fujian Provincial Cancer Hospital, Fuzhou, Fujian, P. R. China.
  • Department of Medical Oncology, Cancer Hospital of Shandong First Medical University, Jinan, Shandong, P. R. China.
  • Department of Oncology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, P. R. China.
  • Department of Clinical Pharmacology, Linyi People's Hospital, Linyi, Shandong, P. R. China.

ORCID-Profile: Jianming Xu

Förderung

  • Shanghai JMT-Bio Technology Co., Ltd

Zitieren

APA

Zhao, C., Zhao, J., Chen, Y., Liu, B., Du, Y., Li, C., Zhang, J., Yang, M., Liu, Y., Bai, Y., Li, S., Zhang, R., Ning, F., Liu, Y., Zou, K., Zhang, Q., Xie, Y., An, Y., & Xu, J. (2025). Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01). Cancer Communications, 45(12), 1755-1759. https://doi.org/10.1002/cac2.70080

Vancouver

Zhao C, Zhao J, Chen Y, Liu B, Du Y, Li C, et al. Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01). Cancer Communications. 2025;45(12):1755-1759. doi:10.1002/cac2.70080

BibTeX
@article{Zhao2025,
  author = {Zhao, Chuanhua and Zhao, Jun and Chen, Yigui and Liu, Bo and Du, Yangfeng and Li, Chenglin and Zhang, Jingdong and Yang, Mudan and Liu, Ying and Bai, Yuxian and Li, Suyi and Zhang, Ruixing and Ning, Fangling and Liu, Yanping and Zou, Kai and Zhang, Qi and Xie, Yijiao and An, Yuping and Xu, Jianming},
  title = {Anbenitamab in combination with chemotherapy in patients with HER2‐positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC‐WISE 01)},
  journal = {Cancer Communications},
  year = {2025},
  volume = {45},
  number = {12},
  pages = {1755--1759},
  doi = {10.1002/cac2.70080}
}
Kostenlos starten →